Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications for
This 12-month analysis in adults with type 1 diabetes using advanced diabetes technology reveals that fear and perceived hypoglycemia frequency do not straightforwardly relate to continuous glucose monitoring metrics, highlighting complex d
This study demonstrates that initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in children and adolescents with cystic fibrosis improves continuous glucose monitoring (CGM) metrics, correlating with better clinical outcomes.
This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.
Experience-based continuous glucose monitoring (CGM) curricula significantly improve internal medicine residents’ confidence in applied patient care skills compared to traditional approaches, supporting hands-on CGM training integrati
This study reveals significant HbA1c and glucose discrepancies, especially in Black individuals, and introduces a personalized HbA1c correction (pA1C) that enhances diabetes management across racial groups.
Suspension of prior authorization requirements led to increased access to CGM and insulin pumps and significant HbA1c improvement in type 1 diabetes patients in a safety net clinic, highlighting benefits of reducing administrative barriers.
Dexcom buys Nutrisense and updates Stelo app with AI; Insulet lowers Omnipod 5 target to 100 mg/dL; Beta Bionics shares real-world iLet HbA1c data.
A population-based study reveals a significant reduction in impaired awareness of hypoglycemia and severe hypoglycemia in youth with type 1 diabetes from 2002 to 2024, indicating substantial progress in diabetes care and the ongoing need fo
This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascu
Among U.S. veterans with diabetes on dialysis, continuous glucose monitoring (CGM) use was associated with significantly lower mortality risk compared to non-CGM use, highlighting CGM’s potential to improve survival in this high-risk
This study demonstrates that nearly half of islet secretory function is preserved following total pancreatectomy with islet autotransplantation (TPIAT), independent of preoperative glycaemic status or prior pancreatic surgery. Continuous gl
This study evaluates gender-based differences in hypoglycaemia symptoms and frequency among people with type 1 and insulin-treated type 2 diabetes using continuous glucose monitoring in real-world settings.
A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower
A six-week native GIP infusion did not improve glucose control in type 2 diabetes, either alone or added to semaglutide, despite raising circulating GIP levels.
The FreeDM2 trial demonstrates that real-time CGM significantly improves HbA1c levels compared to SMBG in adults with type 2 diabetes on basal insulin and modern therapies, with sustained benefits over 32 weeks.
The updated glucose management indicator (uGMI) significantly improves alignment with HbA1c, reducing discordance, particularly in high and low glucose ranges, offering clinicians a more reliable tool for diabetes monitoring.
A randomized trial of 205 pregnant women with gestational diabetes found that adjunctive flash glucose monitoring did not improve time-in-range glucose measurements compared to standard self-monitoring. However, the device was associated wi
This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modali
This post hoc analysis of the WISDM study evaluates whether 52 weeks of continuous glucose monitoring (CGM) improves impaired awareness of hypoglycemia (IAH) in older adults. While severe events decreased, physiological awareness remained l